Primecap Management Co. CA Has $10.99 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Primecap Management Co. CA cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,028,800 shares of the biopharmaceutical company’s stock after selling 23,700 shares during the quarter. Primecap Management Co. CA owned 0.35% of Amicus Therapeutics worth $10,988,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC raised its position in Amicus Therapeutics by 20.1% during the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after acquiring an additional 2,307,385 shares in the last quarter. Millennium Management LLC increased its stake in shares of Amicus Therapeutics by 1,758.9% during the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock worth $18,790,000 after purchasing an additional 1,792,277 shares during the period. William Blair Investment Management LLC lifted its holdings in Amicus Therapeutics by 12.8% during the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after purchasing an additional 1,477,084 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after purchasing an additional 1,192,489 shares during the period. Finally, Squarepoint Ops LLC grew its holdings in Amicus Therapeutics by 159.1% in the 2nd quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company’s stock valued at $6,454,000 after buying an additional 399,449 shares in the last quarter.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders have sold 30,401 shares of company stock worth $352,038. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Up 1.7 %

Shares of FOLD opened at $9.66 on Friday. The firm has a 50 day simple moving average of $10.86 and a two-hundred day simple moving average of $10.58. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a market cap of $2.89 billion, a P/E ratio of -28.41 and a beta of 0.68.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on FOLD. Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 16th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.